Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma

2018

Abstract not available. Disclosures: Study sponsored by Novartis. Copyright 2018 SKIN

Keywords:

Correction
Source
Cite
Save
Machine Reading By IdeaReader

0

References

0

Citations